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Abstract 
Background: Bulbar urethral stricture is a common cause for urinary symptoms in men and its two main treat-
ment options both have drawbacks with little evidence on their relative cost-effectiveness. Current guidelines on 
the management of recurrent bulbar urethral stricture have been predominantly based on expert opinion and panel 
consensus.
Objective: To assess the relative cost-effectiveness of open urethroplasty and endoscopic urethrotomy as treatment 
for recurrent urethral stricture in men.
Methods: Set in the UK National Health Service with recruitment from 38 hospital sites, a randomised controlled trial 
of open urethroplasty and endoscopic urethrotomy with 6-monthly follow-up over 24 months was conducted. Two 
hundred and twenty-two men requiring operative treatment for recurrence of bulbar urethral stricture and having 
had at least one previous intervention for stricture were recruited. Effectiveness was measured by quality- adjusted life 
years (QALYs) derived from EQ-5D 5L. Cost-effectiveness was measured by the incremental cost per QALY gained over 
24 months using a within trial analysis and a Markov model with a 10-year time horizon.
Results: In the within trial, urethroplasty cost on average more than urethrotomy (cost difference: £2148 [95% CI 
689, 3606]) and resulted in a similar number of QALYs on average (QALY difference: − 0.01 [95% CI − 0.17, 0.14)] over 
24 months. The Markov model produced similar results. Sensitivity analyses using multiple imputation, suggested that 
the results were robust, despite observed missing data.
Conclusions: Based on current practice and evidence, urethrotomy is a cost-effective treatment compared with 
urethroplasty.
Keypoints: Urethrotomy and urethroplasty both led to symptom improvement for men with bulbar urethral stric-
ture—a common cause for urinary symptoms in men; Urethroplasty appeared unlikely to offer good value for money 
compared to urethrotomy based on current evidence.
Trial registration: ISRCTN: 98009168 (date: 29 November 2012) and it is also in the UK NIHR Portfolio (reference 13507).
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Introduction
Bulbar urethral stricture is a common cause for urinary 
symptoms (typically difficulty in passing urine) in men. 
Initial treatment is usually by endoscopic urethrotomy, a 
procedure that produces widening of the narrowed ure-
thral segment by incising the stricture internally under 
vision. In about 50% of the cases the stricture will recur 
requiring re-treatment [1]. This can be via a repeat endo-
scopic urethrotomy, graduated dilatation or formally 
repaired by urethroplasty with either excision of the 
stricture and anastomosis, or augmentation using a graft 
such as buccal mucosa.
Urethrotomy is most commonly performed for recur-
rent bulbar stricture because it is minimally invasive, 
does not require specialist surgical expertise, and has a 
short period of urethral catheterisation and recovery. 
However, further recurrence is likely [2]. Open urethro-
plasty is more invasive, requires specialist expertise, a 
longer period of catheterisation and a more protracted 
return to normal activities. Nevertheless, urethroplasty 
may offer the prospect of long-term cure without the 
need for further interventions [3, 4]. When men are 
choosing between these two options, they have to make 
a trade-off between the invasiveness and effectiveness 
of each operation [1, 5–8]. Current decision-making is 
therefore determined by the availability of local exper-
tise, clinician guidance, patient co-morbidity, and patient 
preferences.
The guidelines from the American Urological Associa-
tion (AUA) and Société Internationale d’Urologie (SIU) 
recommend treatment with endoscopic techniques for 
first time bulbar strictures [1]. For recurrent strictures 
the guideline recommendations differ, with the AUA rec-
ommending urethroplasty and the SIU recommending 
endoscopic approaches or urethroplasty if symptomatic 
recurrence is after more than 3 months [1]. The reviews 
underpinning published guidelines, sponsored jointly 
by the SIU, the International Consultation on Urologic 
Disease [1, 5] and by the AUA [7], included non-ran-
domised studies, predominantly of retrospective cohort 
design. Consequently the formulation of the guideline 
recommendation subsequent to these reviews was pre-
dominantly based on expert opinion and panel consensus 
rather than any robust evidence of the relative effective-
ness or cost-effectiveness of these two treatment options.
To address this evidence gap, a randomised controlled 
trial (RCT) was conducted to compare the clinical and 
cost-effectiveness of urethroplasty versus endoscopic 
urethrotomy for the alleviation of urinary symptoms 
in men with recurrent bulbar stricture over 24  months 
(the OPEN (open urethroplasty versus endoscopic ure-
throtomy) Trial [6]). Clinical results of the OPEN trial 
are presented elsewhere [9]. This paper presents the cost-
effectiveness analysis results.
Methods
OPEN was a pragmatic patient-randomised two-arm 
superiority trial, which recruited across 38 National 
Health Service (NHS) secondary care providers in the 
UK. The algorithm allocated participants to each inter-
vention in a 1:1 ratio with recruitment site and time since 
last procedure (< 12 months or ≥ 12 months) as minimi-
sation covariates. Trial procedures and statistical analysis 
are described elsewhere [6, 9].
The OPEN trial’s economic analysis comprised a within 
trial cost-effectiveness analysis and Markov model with a 
10-year time horizon. The within trial analysis estimated 
the costs from a societal perspective, quality adjusted life 
years (QALYs) gained and incremental cost per QALY 
of open urethroplasty compared to endoscopic ure-
throtomy over a 24-month period. As urethroplasty was 
a priori expected to be both more effective and more 
costly than endoscopic urethrotomy, with its benefits 
persisting beyond 24  months, Markov modelling [10] 
was conducted to examine the relative efficiency with 
a 10-year time horizon. Costs were reported as pound 
Sterling for the price year 2017. Where costs came from 
different years they were converted to 2017 values using 
the Consumer Price Index [11], as this was the last full 
year when unit costs were available before the analysis 
Trial protocol: The latest version (1.8) of the full protocol is available at: www. journ alsli brary. nihr. ac. uk/ progr ammes/ 
hta/ 105723/#/ and a published version is also available: Stephenson R, Carnell S, Johnson N, Brown R, Wilkinson J, 
Mundy A, et al. Open urethroplasty versus endoscopic urethrotomy—clarifying the management of men with recur-
rent urethral stricture (the OPEN trial): study protocol for a randomised controlled trial. Trials 2015;16:600. https:// doi. 
org/ 10. 1186/ s13063- 015- 1120-4.
Trial main clinical results publication: Goulao B, Carnell S, Shen J, MacLennan G, Norrie J, Cook J, et al. Surgical Treatment 
for Recurrent Bulbar Urethral Stricture: A Randomised Open-label Superiority Trial of Open Urethroplasty Versus Endo-
scopic Urethrotomy (the OPEN Trial), European Urology, Volume 78, Issue 4, 2020, Pages 572–580.
Keywords: Cost-effectiveness, Economic model, Randomised controlled trial, Urethral stricture, Urethroplasty, 
Urethrotomy
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was conducted. All costs and QALYs were appropriately 
discounted using the recommended discount rate (3.5% 
per annum) [12]. Sensitivity analysis [13] was conducted 
to address uncertainty in study parameters and multiple 
imputation [14] was adopted to deal with missing data.
Resource use and cost
Micro costing methods [15] were used to estimate the 
cost of the two interventions on a per patient basis. The 
cost of the interventions included the staff involved, the 
use of reusable and disposable equipment and use of the 
theatre suite. Data that varied by participant were col-
lected on the trial’s Case Report Form, whilst other data 
came from communications with clinicians at the main 
trial site (Freeman hospital, Newcastle upon Tyne, UK). 
The unit costs of these resources came from standard 
sources [16–18].
When trial participants had a re-intervention during 
the trial’s follow-up period, the same process of micro 
costing used to cost the index procedure was invoked. 
Other use of primary and secondary NHS services, medi-
cations and participants’ out-of-pocket expenses relat-
ing to the condition came from the Case Report Form 
and a bespoke participant cost questionnaire completed 
at six-monthly intervals. Unit costs came from standard 
sources and participant cost questionnaire.
Quality‑adjusted life years
QALYs were based on responses to the EQ-5D-5L col-
lected at baseline, immediately prior to surgery, 1  week 
after catheter removal, 3, 6, 9, 12, 24  months following 
surgery, 18 and 24  months after randomisation and at 
the end of study. The responses to the EQ-5D-5L ques-
tionnaire were scored using UK population tariffs [19] to 
produce a health state utility score for each participant 
in each of the treatment groups using the area under the 
curve (AUC) method [20].
Given the large number of time points for EQ-5D-5L 
data and to align with the primary effectiveness analysis 
[9], it was decided that to be included in the AUC analy-
sis as a complete case, the participant must have at least 
three EQ-5D-5L observations with one at the start of the 
assessment period, one at the mid-range and one at the 
end. The specific requirements depended on whether the 
participants had an initial intervention and the type of 
analysis conducted (details in the note under Table 2).
For all calculations of QALYs, the first observation used 
was set at time point zero and the actual date of comple-
tion for each individual EQ-5D-5L questionnaire was 
used to calculate the number of days from the first obser-
vation. In the sensitivity analyses, QALYs were rescaled 
to the nominal data collection points, i.e. 730  days, to 
account for difference in waiting times between the two 
interventions (note that cost data did not require rescal-
ing in the same way as the recall period, because it was 
pre-defined within the data collection tools). Addition-
ally, multiple imputation for EQ-5D-5L at all missing 
time points was conducted to calculate QALYs for all 
participants.
Within trial cost‑utility analysis
The cost-utility analysis used an intention-to-treat prin-
ciple. The incremental cost-effectiveness ratio (ICER) 
was calculated by dividing the difference in mean costs 
by the difference in mean QALYs for each group. Results 
were presented as point estimates of the mean incre-
mental costs, QALYs and cost per QALY, estimated 
using seemingly unrelated regression [21], controlling 
for dichotomised time since last procedure (less than 
12 months, 12 months or more), allocated treatment arm 
and baseline utility. Multiple imputation was performed 
to complete any missing data and used in the sensitivity 
analysis. Stochastic uncertainty in parameter estimates 
was addressed through the application of bootstrapping 
and the estimation of cost-effectiveness acceptability 
curves.
Markov model
The Markov model consisted of three health states—
symptom-free, symptomatic and deceased—in care path-
ways describing the process of care and disease incidence 
and progression. The base case analysis used parameters 
that were estimated based on information given by study 
participants who were allocated and received the allo-
cated treatment. Both probabilistic and deterministic 
sensitivity analyses were conducted to address uncer-
tainty. Deterministic sensitivity analyses included basing 
model parameters on those who received the same treat-
ment procedure regardless of their allocated interven-
tion group (due to cross-over in the trial) and varying the 
probabilities of follow-up intervention conditional on the 
previous intervention. The parameters used to populate 
the Markov model are reported in supplementary mate-
rial (Additional file 1: Table S1). Model structure is shown 
in supplementary material (Additional file 1: Figure S3).
Results
A total of 222 men were randomised, two of whom were 
excluded from analysis post-randomisation because fur-
ther assessment prior to intervention found them to be 
ineligible. 108 were in the urethroplasty group and 112 in 
the urethrotomy group.
Costs
Total costs combining NHS resource use costs (inter-
vention, re-intervention and health service use 
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during follow-up) and patients’ out-of-pocket costs are 
presented in Table 1. The cost of urethroplasty was statis-
tically significantly  higher over 24 months post randomi-
sation than that of urethrotomy, with the cost difference 
ranging between £1333 and £2123 depending on whether 
follow-up care and patient costs were included for the 
base care and sensitivity analyses. 
Quality‑adjusted life years
Estimates of QALYs for the base case analysis and all the 
sensitivity analyses are presented in Table 2. Urethrotomy 
in general appears to generate higher QALYs than ure-
throplasty. However, the difference was not statistically 
significant apart from evidence of a slight difference for 
the rescaled QALYs at 24  months after surgery (p < 0.1) 
and the rescaled QALYs with imputation (p < 0.1).
Within trial cost‑utility analysis
In the base case, urethroplasty costed more than ure-
throtomy while generating a lower QALY, therefore, 
was dominated by urethrotomy (Table 3). The base case 
results appeared robust as they were similar in the sen-
sitivity analyses (Table 3). The cost-effectiveness accepta-
bility curve (Fig. 1) and incremental cost and QALY plots 
(Additional file  1: Figure S1) are presented for the base 
case.
Markov model
In the base case analysis, urethroplasty is unlikely to be 
considered cost-effective under current society’s willing-
ness to pay threshold for a QALY and this is supported 
by the sensitivity analyses results (Table 4 and Figs. 2 and 
Additional file  1: Figure S2). This is mainly due to the 
higher cost of urethroplasty compared to urethrotomy, 
whilst both of the treatment options produce similar 
QALY gains. This is despite those receiving urethroplasty 
Table 1 Total cost (£) for each trial group
Total cost Urethroplasty Urethrotomy
Mean (SD) £ N Mean (SD) £ N
Base case
Total intervention and re-intervention cost 4332 (3151) 89 2209 (2368) 91
Total NHS cost (intervention and re-intervention with follow-up) 4455 (3191) 89 2657 (3476) 91
Total societal cost (NHS and patient costs) 4480 (3218) 89 2730 (3713) 91
Sensitivity analysis with data imputation
Total intervention and re-intervention cost 4559 (3061) 108 2911 (2713) 112
Total NHS cost (intervention and re-intervention with follow-up) 4674 (3135) 108 3310 (3552) 112
Total societal cost (NHS and patient costs) 4704 (3155) 108 3371 (3755) 112
Table 2 Utility values at each time point and QALYs over the trial follow-up
QALY calculations For those participants who did not receive an initial intervention, to be included in the AUC analysis without imputation, they must have complete 
EQ-5D-5L data on all of the three time points: baseline, 18 months and 24 months after randomisation. For those participants who received an initial intervention, the 
base case analysis examined QALY over the period from baseline to 24 months after randomisation, therefore, the base case AUC analysis required complete EQ-5D-5L 
data at baseline and 24 months after randomisation, and at one of the data collection points of 3, 6, 9, 12 following surgery and 18 months following randomisation. 
Given the differences in the time lengths between randomisation and undergoing an intervention between urethroplasty and urethrotomy, sensitivity analyses also 
examined QALY over the period from the time prior to surgery to 24 month post-surgery, in which case the AUC analysis required complete EQ-5D-5L data at prior to 
surgery and 24 months after surgery, and at one of the data collection points of 3, 6, 9, 12 following surgery and 18, 24 months following randomisation
EQ‑5D 5L Urethroplasty Urethrotomy
Mean (SD) N Mean (SD) N
QALYs at 24 months after randomisation 1.75 (0.40) 55 1.76 (0.35) 54
QALYs at 24 months after randomisation (rescaled to 730 days) 1.66 (0.34) 55 1.70 (0.34) 54
QALY at 24 months after surgery 1.73 (0.54) 44 1.77 (0.34) 56
QALY at 24 months after surgery (rescaled to 730 days) 1.42 (0.40) 44 1.58 (0.30) 56
QALY at 24 months after randomisation with imputation 1.73 (0.32) 108 1.76 (0.28) 112
QALY at 24 months after randomisation with imputation (rescaled to 730 days) 1.67 (0.29) 108 1.72 (0.27) 112
QALY at 24 months after surgery with imputation 1.75 (0.37) 108 1.76 (0.29) 112
QALY at 24 months after surgery with imputation (rescaled to 730 days) 1.67 (0.30) 108 1.72 (0.26) 112
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having a lower chance of recurrence compared to those 
receiving urethrotomy.
Discussion
Relative efficiency within the trial follow-up and over 
a 10-year time horizon was found to favour urethrot-
omy compared with urethroplasty. Effectiveness as 
measured by QALYs appeared to be broadly equivalent 
between the two trial arms of the OPEN trial, and this 
was in line with the primary clinical outcome finding 
showing no statistically significant difference in the pri-
mary patient reported outcome between trial arms [9]. 
Costs were higher in the urethroplasty arm than the 
urethrotomy arm. Therefore, urethroplasty had a higher 
cost whilst producing similar QALY gain, making it 
unlikely to be cost-effective, despite having a lower 
chance of recurrence compared to urethrotomy.
The relatively high cost of urethroplasty is the main 
reason that it was not as cost-effective. It may be pos-
sible to reduce the cost of urethroplasty by using day-
care surgery [22], a shorter period of catheterisation 
[23] or by rationalising follow-up to those most likely to 
need it and discharging symptom stable patients at an 
early stage [24]. Length of stay following urethroplasty 
within the trial was 1.34 (SD 0.95) days vs 0.52 (SD 1) 
for urethrotomy [25]. Therefore, scope to substantially 


























Willingness to pay for a QALY (£)
Urethroplasty
Urethrotomy
Fig. 1 Cost-effectiveness acceptability curve (Base case)







Probability of each treatment strategy is 
cost‑effective for different threshold values for 











Base case Urethroplasty 8026 7.61 301,073 0 0 0 0 2
Urethrotomy 6553 7.60 100 100 100 100 98
Parameters based on treatment received Urethroplasty 7987 7.61 307,328 0 0 0 0 1
Urethrotomy 6490 7.60 100 100 100 100 99
Always receive the same treatment at recurrence Urethroplasty 9026 7.61 476,162 0 0 0 0 0
Urethrotomy 4059 7.60 100 100 100 100 100
Always receive the other treatment at recurrence Urethroplasty 8076 7.61 263,383 0 0 1 2 4
Urethrotomy 7054 7.60 100 100 99 98 96
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stay was reduced to zero this would be insufficient to 
reduce the cost of urethroplasty to close to the cost of 
urethrotomy.
However, the higher cost of urethroplasty is driven by 
the higher theatre procedure and it is unlikely that thea-
tre time could be reduced significantly to alleviate the 
increased costs of urethroplasty. Hospitalisation accounts 
for around 15% of the total intervention cost. Strate-
gies to reduce length of stay could be explored as a way 
of lowering the cost of urethroplasty. In Europe, prac-
tice varies widely with length of stay ranging from 2 to 
7 days in high volume centres exaggerating the difference 
between the two procedures costs. The mean length of 
stay in the UK trial was 2 days. It is unlikely that further 
substantial reductions in length of stay would be possible, 
although pre-operative counselling, improved periopera-
tive analgesia and discharge education could help reduce 
this to 1.5 days.
Although the study showed no difference in effective-
ness as measured by QALYs, it is worth noting that the 
loss of quality of life during recovery from subsequent 
procedures was not taken into consideration. Given the 
likelihood of recurrence requiring repeated treatments, 
this decrement in quality of life could make a difference 
in total QALYs between the two treatments. Patients 
undergoing urethroplasty are also less likely to have 
recurrence in the long-term based on the observation 
during the trial’s follow-up period and consequently suf-
fer less loss in quality of life and hence may accrue more 
QALYs over time. However, there was no obvious signal 
of reductions in quality of life caused by differences in 
recurrent rates [25]. However, this requires further study. 
Additionally, EQ-5D as a generic quality of life meas-
ure may not be sensitive enough to capture changes in 
health-related quality of life among patients with bulbar 
urethral stricture, as the impact on quality of life from 
the condition may fall mostly around the time of recur-
rence or only present in one or two dimensions (e.g. pain, 
anxiety) of EQ-5D. Future research should focus on how 
best to capture quality of life loss during recurrence and 
exploring alternative measures for this type of patients 
using preference elicitation methods [26, 27].
When examining the cost-effectiveness over the long-
term, a key uncertainty in the modelling was the choice 
of re-intervention. The study data showed a large propor-
tion of patients switched to a treatment different from 
their previous treatment when they had a re-interven-
tion. There is no consensus on treatment choices for re-
interventions, and such choices are often influenced by 
many non-clinical factors such as patient choice, wait-
ing time, and travel time [8]. However, varying the prob-
abilities of treatment options conditional on the previous 
intervention in the sensitivity analyses conducted for the 
modelling showed that urethroplasty remained less likely 
to be cost-effective.
Due to the trial’s follow-up period of two years, we 
could potentially be underestimating the costs of the 

























Willingness to pay for a QALY (£)
Urethroplasty
Urethrotomy
Fig. 2 Cost-effectiveness acceptability curve (Markov model base case)
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many recurrences there need to be to offset the more 
expensive urethroplasty and over what length of time. 
On the other hand, there was little evidence suggesting 
patients’ quality of life differed significantly between 
the two arms, at least within the trial’s follow-up 
period. We do not claim that cost is the only concern 
in the choice of treatment, but in the absence of clear 
evidence on the additional benefits one treatment can 
bring, costs may be an important factor to consider 
in a publicly funded health system. These issues were 
also extrapolated over 10 years using a Markov model, 
which met or exceeded internationally accepted guide-
lines for best practice for the conduct of such work. 
This analysis showed that the initial higher costs of ure-
throplasty were not likely to be offset by increased rein-
tervention rates but that urethroplasty was on average 
more effective.
The key strength of the present study is the use of an 
RCT designed to detect the clinically meaningful dif-
ference in voiding symptom score. The RCT design was 
based on current best practice for pragmatic surgical tri-
als and it sought to provide direct and most up to date 
information on costs and utilities. However, obtaining 
data directly from a large clinical study also has its down-
side. The principle limitation of the RCT was the missing 
data caused by trial participants being lost to follow-up; 
a common situation in a complex study involving several 
years of follow-up. We remedied this by using multiple 
imputation for the missing data and comparing complete 
case analysis with analyses using imputation. These sen-
sitivity analyses demonstrated that the study results were 
robust.
Although the economic evaluation was conducted in 
the UK NHS, the results are generalisable to other coun-
tries with similarly public funded healthcare systems. 
As we have seen that there is little difference in QALYs 
between the two treatment options, regardless of unit 
costs of resources used, urethroplasty is generally more 
costly than urethrotomy due to the longer operating 
and recovery time. Therefore, the conclusions drawn for 
QALYs and costs would stay unchanged in other settings.
Conclusions
This paper has presented a comprehensive economic 
analysis of the relative efficiency of urethroplasty and 
urethrotomy within an RCT over 24 months and over a 
10-year time horizon. Based on current practice and evi-
dence, urethroplasty is unlikely to be cost-effective due to 
its higher cost. Future research should examine how the 
benefits of reduced recurrence by urethroplasty can be 
captured while finding ways to reduce its costs.
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